Introduction
Sialic acids commonly presented as the terminal residues on mammalian oligosaccharides or glycoconjugates are key recognition components of bacterial adhesins, viral surface proteins, selectins, Siglecs, and other sialic acid-binding proteins involved in infection, inflammation, cancer metastasis, and immunoregulation. [1] [2] [3] [4] Sialic acids present tremendous structural diversity in nature and more than 50 members have been identified so far. These include N-acetylneuraminic acid (Neu5Ac), the non-human sialic acid N-glycolylneuraminic acid (Neu5Gc), 2-keto-3-deoxy-nonulosonic acid (Kdn), their derivatives with single or multiple O-acetylation and less frequent 8-O-methylation, 8-O-sulfation, 9-O-lactylation, or 9-O-phosphorylation.
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O-Acetylation is the most frequently occurring modification of sialic acids. Single or multiple O-acetylation at positions 4, 7, 8 , and/or 9 of sialic acid has been identified and the presentation varies among different types of species, organs, and cells. [1] [2] [3] [4] Comparing to 9-O-acetylation which is the most common sialic acid O-acetylation, 4-O-acetylated sialic acids ( Fig. 1 ) including 4-O-acetyl-N-acetylneuraminic acid (Neu4,5Ac 2 , 1) and 4-O-acetyl-N-glycolylneuraminic acid (Neu4Ac5Gc, 2) are less common. 5 Neu4,5Ac 2 (1) has been found in horse, 6 donkey, 7 Australian monotreme Echidna, 5, 8 Japanese dace, 9 South American pit viper, 10 rabbit, 11 guineapig. 6 Neu4,5Ac 2 -containing oligosaccharides have been found to be the dominant components of the acidic milk oligosaccharides (MOSs) of monotremes echidnas and platypus. [12] [13] [14] Both Neu4,5Ac 2 and Neu4Ac5Gc have been found in horse glycoproteins. 5 The presence of Neu4Ac5Gc-GM3 ganglioside in human colon cancer tissues was detected using purified antibodies. 15 Neu4Ac5Gc (2) has also been found in α2-8-linked polysialic acids of glycoproteins from unfertilized kokanee salmon egg 16 and in the serum of guinea pig in trace amounts. 4-O-Acetylation of sialic acids provides resistance or decreased sensitivity of sialosides to various sialidases. 6, 18, 19 This property is believed to contribute to the inhibitory activity of Neu4,5Ac 2 -rich horse and guinea pig α 2 -macroglobulins against hemagglutination and infectivity of several human influenza viruses. 6, 18, 19 On the other hand, Neu4,5Ac 2 is selectively recognized by the hemagglutinin-esterase (HE) 20, 21 of mouse hepatitis virus strain S (MHV-S), a type of murine coronavirus, and infectious salmon anemia virus (ISAV). 22 Nevertheless, the significance of naturally existing 4-Oacetylated sialic acids is not well understood partly due to the lack of access to sufficient amounts of the corresponding sialosides.
To our knowledge, the synthesis of sialosides containing 4-O-aceylated sialic acids by either chemical or enzymatic methods has not been reported. Here we present a facile chemoenzymatic approach for preparative and gram-scale synthesis of monotreme milk oligosaccharides including Neu4,5Ac 2 -containing α2-3-linked sialyl lactose (Neu4,5Ac 2 α3Lac) and sialyl lacto-N-neotetraose (Neu4,5Ac 2 α3LNnT). Other Neu4,5Ac 2 -or Neu4Ac5Gc-containing α2-3-linked sialosides representating common terminal sialosides in mammals are also synthesized.
Results and discussion
We envisioned that the desired 4-O-acetyl-sialic acidcontaining sialosides could be chemoenzymatically synthesized using an effective one-pot two-enzyme sialylation system containing a cytidine 5'-monophosphate-sialic acid (CMP-Sia) synthetase (CSS) and a sialyltransferase (ST). 23 To test the feasibility, the corresponding 4-O-acetyl-sialic acids were chemically synthesized. As shown in Scheme 1, Neu4,5Ac 2 (1) was synthesized from N-acetylneuraminic acid (Neu5Ac, 3) by esterification of the C1-carboxyl group with benzyl bromide to provide benzyl ester 4 with a 90% yield. Protection of 4 at C8 and C9 by adding 2,2-dimethoxypropane in the presence of a catalytical amount of p-toluenesulfonic acid produced partially protected 5 in an excellent 92% yield. Regioselectively acetylation of 5 at O-4 using acetic anhydride in pyridine at room temperature provided the key intermediated 6 in a 81% yield. Final deprotection of the O-isopropylidene group in 6 by treating with 80% acetic acid and removal of the benzyl ester group by catalytic hydrogenolysis with H 2 in the presence of Pd/C in methanol resulted in Neu4,5Ac 2 (1) in a 82% yield. The obtained product has a proton nuclear magnetic resonance ( 1 H NMR) spectrum consistent with that reported. 24 The 4-O-acetyl modification caused a downfield shift of Neu5Ac H-4 signal.
Scheme 1 Chemical synthesis of Neu4,5Ac2 (1).
Neu4Ac5Gc (2) was chemoenzymatically synthesized from D-mannosamine hydrochloride (ManNH 2 ⋅HCl, 7). As shown in Scheme 2, N-(2-Benzyloxyacetyl)-D-mannosamine 8 was obtained by treating ManNH 2 ⋅HCl (7) with 2-benzyloxyacetyl chloride in the presence of NaHCO 3 in CH 3 CN and water. P. multocida sialic acid aldolase (PmNanA) 25 -catalyzed aldol reaction of 8 with sodium pyruvate at 37 °C for 48 h produced the corresponding sialic acid derivative 9 in an excellent quantitative yield. The introduction of 4-O-acetyl group was carried out similarly to that described above for the synthesis of Neu4,5Ac 2 (1). Briefly, selective benzoylation of 9 with benzyl bromide formed benzyl ester 10 in a 90% yield. Treating 10 with 2,2-dimethoxypropane produced 8,9-isopropylideneprotected 11 in a 96% yield. Selective acetylation of benzoate 11 with Ac 2 O and pyridine produced the corresponding 4-Oacetyl derivative 12 in a good yield (81%). Subsequent removal of the isopropylidene group using HOAc/H 2 O followed by debenzylation using catalytic hydrogenation produced the target Neu4Ac5Gc (2) in a 78% yield.
Scheme 2 Chemoenzymatic synthesis of Neu4Ac5Gc (2).
Sialyltransferase-catalyzed reactions use CMP-sialic acids which can be potentially accessed by a suitable CMP-Sia synthetase (CSS, EC 2.7.7.43). The tolerance of using Neu4,5Ac 2 (1) as a potential substrate was tested for several bacterial CSSs including those from Neisseria meningitidis (NmCSS), 26 Pasteurella multocida (PmCSS), Haemophilus ducreyi (HdCSS), as well as two NmCSS mutants (NmCSS_S81R and NmCSS_Q163A). 27 Small-scale reactions carried out in TrisHCl buffer (100 mM, pH 7.1) at 37 °C for 15 h followed by thinlayer chromatography (TLC) and mass spectrometry (MS) analyses indicated that all CSSs tested could use Neu4,5Ac 2 (1) efficiently (Fig. S1 , †ESI). These results were quite exciting as a previous report showed that CSSs purified from calf brain, bovine, and equine submaxillary glands could not use Neu4,5Ac 2 (1) as a substrate for the synthesis of the corresponding CMP-sialic acid. 28 NmCSS was chosen for further studies and for preparative-scale and gram-scale syntheses.
Scheme 3
One-pot two-enzyme (OP2E) synthesis of sialosides containing Neu4,5Ac2 (1) or Neu4Ac5Gc (2) . Enzymes: NmCSS, Neisseria meningitidis CMP-sialic acid synthetase; PmST3, Pasteurella multocida α2-3-sialyltransferase 3. The pH of the reaction was controlled at 7.1 to minimize de-O-acetylation during the enzymatic reaction. Yields were calculated for purified products based on the amounts of acceptors (limiting reagents) used.
A coupled enzymatic assay was used to evaluate several bacterial sialyltransferases in using CMP-Neu4,5Ac 2 and CMPNeu4Ac5Gc synthesized in situ by NmCSS from Neu4,5Ac 2 (17) and GlcNAc in a 94% yield using a one-pot four-enzyme (OP4E) GlcNAc activation and transfer system containing Bifidobacterium longum N-acetylhexosamine-1-kinase (BLNahK, NahK_ATCC55813), 43 Pasteurella multocida Nacetylglucosamine uridyltransferase (PmGlmU), 44 Pasteurella multocida inorganic pyrophosphatase (PmPpA), 40 and Neisseria meningitidis β1-3-N-acetylglucosaminyltransferase (NmLgtA). [45] [46] [47] LNnTβProN 3 (23) 42 was then produced from Lc 3 and galactose in an excellent (99%) yield using a OP4E galactosylation system 37, 39 containing Escherichia coli galactokinase (EcGalK), 48 Bifidobacterium longum UDP-sugar pyrophosphorylase (BLUSP), 49 PmPpA, 40 and Neisseria meningitidis β1-4-galactosyltransferase (NmLgtB).
40, 47
Synthesis of Neu4,5Ac 2 α3LNnTβProN 3 (34) from LNnTβProN 3 (23) and Neu4,5Ac 2 (1) was successfully achieved in a good 81% yield using NmCSS and PmST3 in one-pot (Scheme 3). Although less efficient compared to the synthesis of their Neu4,5Ac 2 -containing matching pairs, Neu4Ac5Gc-containing α2-3-linked sialosides with a propyl azide aglycone (35) (36) (37) (38) (39) (40) (41) were successfully obtained from Neu4Ac5Gc (2) and the corresponding disaccharides (17) (18) (19) (20) (21) (22) or tetrasaccharide (23) in 51-71% yields using the OP2E sialylation reaction (Scheme 3). This indicated that CMP-Neu4,5Ac 2 generated in situ is a better donor substrate than in situ generated CMP-Neu4Ac5Gc for PmST3. Longer reaction time needed for the synthesis of Neu4Ac5Gc-containing compounds also led to de-Oacetylation which also contributed to lower sialylaton yields.
All sialoside products synthesized in preparative scale were purified by gel filtration chromatography and semi-prep highperformance liquid chromatography (HPLC) using a reversephase C18 column. The structures were characterized by 1 H and 13 C nuclear magnetic resonance (NMR) spectroscopy as wells as high resolution mass spectrometry (HRMS). Neu4,5Ac 2 α3Lac (24) synthesized in gram scale was purified (1.33 g) using a CombiFlash® Rf 200i system with a ODS-SM column (51 g, 50 µM, 120 Å, Yamazen). The synthesized pNP-tagged sialoside Neu4,5Ac 2 α3GalβpNP (27) was used in a 384-well plate-based high-throughput colorimetric assay 50 for substrate specificity studies of the α2-3-sialidase activity of Pasteurella multocida sialyltransferase 1 (PmST1), 29 four commercially available bacterial sialidases, and four human influenza A viruses. 51 While all bacterial sialidases tested including PmST1 as well as commercially available sialidases from Arthrobacter ureafaciens (Prozyme), Clostridium perfringens (Prozyme), Vibrio cholerae (Prozyme), and Streptococcus pneumoniae (Prozyme) did not show any sialidase activity towards Neu4,5Ac 2 α3GalβpNP (27) under the conditions used, human influenza A viruses (presumably the surface neuraminidases) could hydrolyze it ( Fig. 2 black columns) . As expected, all bacterial sialidases and viruses tested could cleave non-Oacetylated sialoside Neu5Acα3GalβpNP 50 which was used as a positive control ( Fig. 2 white columns). In order to test whether the cleavage of Neu4,5Ac 2 by human influenza A viruses was caused by de-O-acetylation or direct de-sialylation, Neu4,5Ac 2 α3Lac was incubated with purified human influenza A virus strain A/Puerto Rico/34/8 H1N1 (A/PR8) followed by high-resolution mass spectrometry analysis. Major product peak for Neu4,5Ac2 was seen and only a trace amount of Neu5Ac was observed, indicating a direct de-sialylation of Neu4,5Ac 2 mechanism was used by human influenza A viruses.
Conclusions
In conclusions, we report here a convenient and efficient chemoenzymatic sialylation approach for synthesizing α2-3-linked sialosides containing a 4-O-acetylated sialic acid. PmST3, but not other bacterial sialyltransferases, was identified as a unique sialyltransferase that can catalyze the transfer of 4-Oacetylated sialic acid. Using chemically or chemoenzymatically synthesized Neu4,5Ac 2 (1) or Neu4Ac5Gc (2), α2-3-linked sialosides were readily obtained by a one-pot two-enzyme (OP2E) system containing NmCSS and PmST3. Using Neu4,5Ac 2 α3GalβpNP as an effective probe, substrate specific studies showed that while Neu4,5Ac 2 was not hydrolyzed by bacterial sialidases tested, it was effectively removed by human influenza A virus neuraminidases.
Experimental Section
Materials and methods. Chemicals were purchased and used as received. NMR spectra were recored in the NMR facility of University of California, Davis on a Varian Inova 400 (400 MHz for 1 H, 100 MHz for 13 C) and a Bruker Avance-800 NMR spectrometer (800 MHz for 1 H, 200 MHz for 13 C). Chemical shifts are reported in parts per million (ppm) on the δ scale. High resolution (HR) electrospray ionization (ESI) mass spectra were obtained using a Thermo Electron LTQ-Orbitrap Hybrid MS at the Mass Spectrometry Facility in the University of California, Davis. Silica gel 60 Å (230-400 mesh, Sorbent Technologies) was used for flash column chromatography. Thin layer chromatography was performed on silica gel plates (Sorbent Technologies) using anisaldehyde sugar stain for detection. Gel filtration chromatography was performed with a column (100 cm × 2.5 cm) packed with Bio-Gel P-2 Fine resins (Bio-Rad). D-Galactose (Gal) and N-acetyl-D-glucosamine (GlcNAc) were from Fisher Scientific. GalβpNP was from Sigma. N-Acetyl-D-mannosamine (ManNAc) and N-acetylneuraminic acid (Neu5Ac) was from Inalco (Italy). Adenosine 5'-triphosphate (ATP), uridine 5'-triphosphate (UTP), and cytosine 5'-triphosphate (CTP) were purchased from Hangzhou Meiya Pharmaceutical Co. Ltd. Lacto-N-tetraose (LNT) was from Elicityl (Crolles, France). Aspergillus oryzae β-galactosidase was from Sigma (St. Louis, MO). Recombinant enzymes Bifidobacterium longum strain ATCC55813 Nacetylhexosamine-1-kinase (BLNahK or NahK_ATCC55813), 43 Pasteurella multocida N-acetylglucosamine uridyltransferase (PmGlmU), 44 Pasteurella multocida inorganic pyrophosphatase (PmPpA), 40 Neisseria meningitidis β1-3-Nacetylglucosaminyltransferase (NmLgtA), 45, 46 Escherichia coli galactokinase (EcGalK), 48 Bifidobacterium longum UDP-sugar pyrophosphorylase (BLUSP), 49 Neisseria meningitidis β1-4-galactosyltransferase (NmLgtB), 40 Pasteurella multocida sialic acid aldolase (PmNanA), 25 Neisseria meningitidis CMP-sialic acid synthetase (NmCSS), 26 Pasteurella multocida CSS (PmCSS), Haemophilus ducreyi CSS (HdCSS), and two NmCSS mutants (NmCSS_S81R and NmCSS_Q163A), 27 and Pasteurella multocida multifunctional α2-3-sialyltransferase 3 (PmST3) 31 were expressed and purified as described previously. Purified human influenza A viruses A/Puerto Rico/34/8 H1N1 (A/PR8), A/Philippines/2/82/X-79 H3N2 (A/Philips), A/Memphis/71 H3N1 (A/Mem71), and A/Udorn/307/72 H3N2 (A/Udorn72) were described previously. 2 mmol) in water (20 mL), 10% Cs 2 CO 3 was added dropwisely to adjust the pH value of solution to neutral. The reaction mixture was then evaporated and dried for overnight using a vacuum pump. The obtained solid was dissolved in N,N-dimethylformamide (20 mL), and benzyl bromide (3 mL) was added dropwisely. The mixture was stirred under argon for overnight at room temperature and then filtered. The filtrate was evaporated to produce a syrup. Crystallization using 2-propanol produced 4 (5.8 g, 90% 55 mmol) in pyridine (4 mL), acetic anhydride (2 mL) was added. The mixture was stirred for 1 h at room temperature and then ethanol (10 mL) was added. The solution was evaporated to dryness and the residue was purified by a silica gel column (EtOAc:Hexane = 2:1, by volume) to produce compound 6 (1.7 g, 81% Multigram scale synthesis of Neu4,5Ac 2 (1). A multigram scale synthesis of Neu4,5Ac 2 (1) was also achieved using the procedure described above. Briefly, Neu5Ac (10.1 g, 32.65 mmol) was dissolved in water (50 mL) and 10% Cs 2 CO 3 was added to adjust the solution to neutral. After removal of the solvent and dried under vacuum, the obtained solid was dissolved in dry DMF (60 mL), and benzyl bromide (6 mL) was added at 0 °C. The mixture was stirred at room temperature under argon for overnight and then filtered. The filtrate was evaporated to a syrup which was crystallized using 2-propanol to produce 4 (11.1 g, 85%). Compound 4 (10.08 g, 25.23 mmol) was then dissolved in acetone (150 mL), and 2,2-dimethoxypropane (20 mL) and camphorsulfonic acid (150 mg) were added. The mixture was stirred at room temperature for 2 hours. Trimethylamine (500 µL) was added and the mixture was stirred for 15 min before it was concentrated. The obtained residue was purified using a 150 g RediSep Rf silica column (EtOAc:MeOH = 5:1, by volume) on a CombiFlash® Rf 200i system to produce 5 (10.5 g, 95%). Compound 5 (9.89 g, 22.50 mmol) was dissolved in pyridine (40 mL) and Ac 2 O (15 mL) was added. The mixture was stirred for 1 h at room temperature and ethanol (30 mL) was added at 0 °C. After being concentrated, the residue was purified using a 150 g RediSep Rf silica column (EtOAc:MeOH = 10:1, by volume) on a CombiFlash® Rf 200i system to produce compound 6 (9.1 g, 84%). A solution of compound 6 (8.58 g, 17.83 mmol) in 90% acetic acid (40 mL) was stirred at 60 °C for 2 h. The reaction mixture was evaporated and the obtained syrup was dissolved in methanol (50 mL) and treated with H 2 in the presence of 10% Pd/C for 2 h at room temperature. The solution was filtered and concentrated. The residue was purified using a ODS-SM column (51 g, 50 µM, 120 Å, Yamazen) on a CombiFlash® Rf 200i system and was eluted with a gradient of 0-100% acetonitrile in water containing 0.05% formic acid over 30 minutes with a 30 mL/min flow rate. The fractions containing the pure product were collected and concentrated to produce the final product 1 (5.2 g, 83%) as a white powder.
Synthesis of Neu4Ac5Gc (2)
N-(2-Benzyloxyacetyl)-D-neuraminic acid (9). Solid K 2 CO 3 (14.4 g, 104.3 mM) was added to a stirred mixture of ManNH 2 . HCl (7, 4.5 g, 20.8 mM) in dry MeOH (100 mL). The mixture was stirred for 30 min and benzyloxyacetyl chloride (5.8 g, 31.3 mM) was added dropwisely. When the reaction was completed as monitored by TLC, the mixture was concentrated and purified by flash chromatography (DCM:MeOH = 10:1, by volume) to produce ManNGc analog 8 (5.8 g, 85%). Compound 8 (3.5 g, 10.7 mM) and pyruvate (4.11 g, 37.4 mM) were dissolved in water (35 mL) in a 50 mL centrifuge tube. After the addition of an appropriate amount of PmNanA (52 mg), the reaction mixture was incubated in an isotherm incubator for 48 h at 37 °C with gentle shaking. The reaction progress was monitored by TLC (nPrOH:H 2 O:HOAc = 5:2:1, by volume) and mass spectrometer (MS). When the reaction was completed, ice-cold ethanol (35 mL) was added and the reaction mixture was incubated at 4 °C for 30 min. The mixture was centrifuged and the supernatant was concentrated. 
Benzyl

5-glycolylamido-3,5-dideoxy-D-glycero-β β β β-D-galacto-2-nonulopyranosonate (10).
To a stirring solution of Neu5GcOBn (9, 3.0 g, mmol) in water (25 mL), 10% CsCO 3 was added dropwisely to adjust pH to neutral. The solution was then evaporated and the residue was dried for overnight by a vacum pump to produce the cesium salt of Neu5GcOBn. The salt was dissovled in N,Ndimethylformamide (40 mL), benzyl bromide (1.5 mL) was then added to the solution. The mixutre was strired under argon for 2 h at room temperature. After evaporation, the residue was purified by silica gel column chromatography (EtOAc 
5-Glycolylamido-4-O-acetyl-3,5-dideoxy-D-glycero-β β β β-D-galacto-2-nonulopyranosonate (2).
To a solution of 8,9-O-isopropylideneNeu5GcOBn (11, 1.1 g, 2.02 mmol) in pyridine (4 mL), acetic anhydride (2 mL) was added. The mixture was stirred for 1 h at room temperature and ethanol (10 mL) was added. The solution was evaporated to dryness and the residue was purified by a silica gel column (EtOAc:toluene = 1:2, by volume) to produce compound 12 (0.96 g, 81%). A solution of compound 12 (0.8 g, 1.36 mmol) in 90% acetic acid was stirred for 2 h at 60 °C. The reaction mixture was evaporated to give a syrup which was dissolved in methanol (20 mL) and treated with H 2 in the presence of 10% Pd/C for 2 h at room temperature. The solution was filtered through Celite and concentrated. The residue was purified by a silica gel column 2 eq, 1 or 2) , and CTP (2.0 eq), MgCl 2 (20 mM) were dissolved in Tris-HCl buffer (100 mM, pH 7.1), containing NmCSS (3 mg/mL), and PmST3 (5 mg/mL). The reaction mixture was incubated at 37 °C in an incubator with agitation (100 rpm) for 14 h. The product formation was monitored by MS. The reaction was terminated by adding the same volume (10 mL) of ice-cold EtOH followed by incubation at 4 °C for 30 min. The mixture was centrifuged to remove precipitates. The supernatant was concentrated and passed through a Bio-gel P-2 gel filtration column with water as the eluate to obtain the desired product. The compound was further purified by a reverse-phase C18 column (Phenomenex, 10 µm, 21.2 × 250 mm) with a flow rate of 10 mL/min using a gradient elution of 0-100% acetonitrile in water containing 0.05% formic acid over 20 minutes [Mobile phase A: 0.05% formic acid in water (v/v); Mobile phase B: acetonitrile (v/v); Gradient: 0% B for 3 minutes, 0% to 100% B over 12 minutes, 100% B for 2 minutes, then 100% to 0% B over 3 minutes]. The fractions Neu4,5Ac 2 Neu4,5Ac 2 α α α α3Galβ β β βpNP (27). 13 mg, yield 31%; white solid. Gram-scale OP2E synthesis of monotreme milk trisaccharide Neu4,5Ac 2 α α α α3Lac. Lactose (1.09 g, 3.05 mmol), Neu4,5Ac 2 (1.07 g, 3.05 mmol), and CTP (1.93 g, 3.66 mmol) were dissolved in water (30 mL) and the pH of the solution was adjusted to 7.1 using NaOH solution (4 M). MgCl 2 (20 mM), Tris-HCl buffer (100 mM, pH 7.1), NmCSS (15 mg), and PmST3 (20 mg) were then added and the total volume of the reaction mixture was brought up to 100 mL by adding H 2 O. The reaction mixture was incubated in an incubator shaker with shaking (100 rpm) at 30 °C for overnight. The reaction was monitored by mass spectrometry (MS). Additional CTP (0.96 g) was added to the reaction mixture and the pH was carefully adjusted to pH 7.1 using NaOH solution (4 M). The reaction was allowed to continue for another 20 h at room temperature until an optimal yield was achieved. After adding ethanol (100 mL), the reaction mixture was incubated at 4 °C for 1 h. The precipitates were removed by centrifuge and the supernatant was concentrated. The residue was purified using a ODS-SM column (51 g, 50 µM, 120 Å, Yamazen) on a CombiFlash® Rf 200i system. Mobile phase A: water; Mobile phase B: acetonitrile; Gradient: 10% B for 6 minutes, 10% to 100% B over 12 minutes, 100% B for 6 minutes, then 100% to 80% B over 1 minutes. The fractions containing the pure product were collected and concentrated to produce the final purified product Neu4,5Ac 2 α3Galβ4Glc (1.33 g, 71%) as a white powder. The identity and the purity of the product were confirmed by NMR and HRMS.
Sialidase assays. Sialidase assays were carried out in duplicate at 37 °C for 40 min (for bacterial sialidases) or 30 min (for human influenza A viruses) in a 384-well plate (Fisher Scientific, Chicago, IL) in a final volume of 20 µL containing Neu4,5Ac 2 α3GalβpNP (0.3 mM) and Aspergillus oryzae β-galactosidase (12 µg, 126 mU) . The amount of the β-galactosidase required to completely hydrolyze GalβpNP (0.3 mM) within the time frame of the assay was predetermined and confirmed by control assays with GalβpNP (0.3 mM). The reactions were stopped by adding 40 µL of N-cyclohexyl-3-aminopropane sulfonic acid (CAPS) buffer (0.5 M, pH 11.5). The amount of para-nitrophenolate formed was determined by measuring the A 405 nm of the reaction mixtures using a microtiter plate reader. Neu5Acα3GalβpNP 50 was used as a control.
The assay conditions for bacterial sialidases were: A. ureafaciens sialidase (1.5 mU) in sodium acetate buffer (100 mM, pH 5.5); C. perfringens sialidase (3 mU) in MES buffer (100 mM, pH 5.0); V. cholerae sialidase (1.5 mU) in sodium acetate buffer (100 mM, pH 5.5) containing NaCl (150 mM) and CaCl 2 (10 mM); S. pneumoniae sialidase (1.5 mU) in sodium acetate buffer (100 mM, pH 6.0); PmST1 (10 µg) in sodium acetate buffer (100 mM, pH 5.5). Viral sialidase assays were carried out in a MES buffer (100 mM, pH 5.0) containing a purified human influenza A virus (1×10 5 HAU mL To test whether the cleavage of Neu4,5Ac 2 by human influenza A viruses was caused by de-O-acetylation or direct de-sialylation, Neu4,5Ac 2 α3Lac (1 mM) was incubated with purified human influenza A virus strain A/Puerto Rico/34/8 H1N1 (A/PR8) (1×10 5 HAU mL −1 ) in a MES buffer (100 mM, pH 5.0) for 30 min at 37 °C.
The reaction mixture was then subjected to high-resolution mass spectrometry analysis.
